麻豆传媒

Chronic inflammation underlies pathologies as seemingly diverse as cancer, allergy, and a festering wound. My research focuses on discovering the dysfunctional molecular signals and circuitry causing cells to become bad actors, and why some people are more prone to these problems than others. In the lab we do this by examining signal transduction in cells differentiated from adult stem cells, particularly mast cells, macrophages, immature myeloid cells, and different populations of mesenchymal stem cells. We also use in vivo modeling to observe the consequences of targeting certain pathways in inflammatory diseases. The lab's broad areas include (1) Mast Cell Biology; (2) Inflammatory Modulation; and (3) Immune Cell Dynamics in Cancer. Our ultimate goals are to better understand the diversity of innate and adaptive immune responses, and contribute knowledge to more individually tailored approaches for treatment. Current projects include: Signaling networks (esp. TGF-β1) and differential expression of myeloid cells during inflammation and in response to immunosuppression Off-label drug uses and novel compounds, such as plant alkaloids and cannabinoids, for healthful resolution of inflammatory responses Cellular & molecular mechanisms underlying complementary and integrative health practices such as exercise. Trained immunity (a.k.a. "innate memory") of mast cells in cancer and autoimmunity Targeting mast cell specific receptors during inflammation Education Postdoctoral: Molecular Immunology, Department of Biology, Virginia Commonwealth University, Richmond, VA Ph.D.: Anatomy & Neurobiology, Virginia Commonwealth University School of Medicine, Richmond, VA B.S.: Biology, James Madison University, Harrisonburg, VA Professional Affiliations: American Association of Immunologists Society for Leukocyte Biology American Association for Anatomy American Association for the Advancement of Science

Jan Kitajewski, PhD, is the Director of the University of Illinois Cancer Center and head of the Department of Physiology and Biophysics at the University of Illinois Chicago (UIC). His research is focused on tumor angiogenesis, cell fate determination, GPCR signaling and pathway remodeling. His specific areas of focus are vessel development, reproductive angiogenesis and tumor angiogenesis associated with breast and ovarian cancer. His lab established that Notch functions in tumor angiogenesis and developed therapeutic strategies to treat gynecological malignancies and breast cancer. Kitajewski received his PhD from Princeton University. Previously, he served at Columbia University as Co-Director of the Cancer Signaling Networks program at Herbert Irving Comprehensive Cancer Center (HICCC) and Director of the Division of Reproductive Sciences in the Department of Ob/Gyn.

Scientist Andrew Ewald studies how cells work together, organize and form organs in early development. Cancer cells co-opt these mechanisms to break away from a tumor and form metastatic sites all over the body.

Altieri is interested in how mechanisms of cellular adaptation or “plasticity” are universally exploited in cancer for disease maintenance and progression. Multiple cellular pathways of response to stress, metabolic rewiring, and control of cell death are invariably subverted in human tumors, and often confer more aggressive disease traits including the ability to disseminate to distant organs, or metastasis. A detailed, molecular, cellular, and genetic understanding of tumor plasticity could uncover new therapeutic targets and identify novel approaches to interfere with metastatic competence, which remains the primary cause of death for cancer patients. Born in Milan, Italy, and educated at the University of Milan School of Medicine, Altieri is a physician-scientist trained in internal medicine and holds a postgraduate degree in clinical and experimental hematology. In 1987, he joined the Scripps Clinic and Research Foundation in La Jolla, California, first as a research fellow and later as a member of the faculty. In 1994, Altieri became an associate professor at the Boyer Center for Molecular Medicine at Yale University School of Medicine, where he was named professor with tenure in 1999 and member of the Yale Cancer Center executive committee. In 2002, Altieri was recruited as the founding chair of the Department of Cancer Biology at the University of Massachusetts Medical School and Director of the UMass Memorial Cancer Center. Altieri joined the Institute as the Wistar Cancer Center Director and its first Chief Scientific Officer in September 2010. He was appointed as President and Chief Executive Officer of Wistar in 2015 while continuing to serve as Director of the recently renamed National Cancer Institute (NCI)-designated Ellen and Ronald Caplan Cancer Center.

Auslander focuses on developing machine learning methods to understand genetic and infectious factors that drive cancer evolution and identify patterns that can improve cancer diagnosis and treatment. Auslander earned her B.S. in computer science and biology from Tel Aviv University and continued her studies in Maryland, where she obtained a computer science Ph.D. from the University of Maryland with a combined fellowship at the National Cancer Institute. She received postdoctoral training at the National Center of Biotechnology Information (NCBI) and joined The Wistar Institute in 2021 as an assistant professor.

Liang’s research explores basic mechanisms underlying fundamental cellular processes in inflammation, infection, and cancer, broadly focusing on autophagy, organelle homeostasis, genomic stability, membrane trafficking, and virus-host interaction. Liang obtained her M.D. degree from Qingdao University School of Medicine, China, and her Ph.D. degree in genetics from State University of New York (SUNY) at Stony Brook. She received postdoctoral training in tumor virology at Harvard Medical School in the Department of Microbiology and Molecular Genetics. She established her laboratory in 2009 in the Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine in Los Angeles, where she was promoted to tenured associate professor in 2015. Liang joined The Wistar Institute as a professor in 2020.

Montaner studies the mechanisms of disease in HIV-1 infection and cancer, exploring new strategies to boost the natural function of the immune system in order to combat viral-associated disease or cancer progression. Montaner obtained his D.V.M., Veterinary Medicine from Kansas State University in 1989 and his D.Phil. in Experimental Pathology from University of Oxford, Oxford, U.K., in 1995. He joined The Wistar Institute in 1995 as an assistant professor and was promoted to professor in 2007.

Murphy studies the genetics of the p53 tumor suppressor protein. Her laboratory focuses on genetic variants of p53 that exist in populations of African-descent (P47S and Y107H) and Ashkenazi Jewish descent (G334R). Her work seeks to understand the impact of these genetic variants of p53 on cancer risk and the efficacy of cancer therapy. She also seeks to identify personalized medicine approaches for tumors with these variants. Therefore, her work has direct relevance for improving the cancer prognosis and therapy of African and Ashkenazi Jewish Americans. Murphy also studies the cancer-survival protein HSP70. Her lab employs a novel series of HSP70 inhibitors for melanoma and colorectal cancer therapy. Murphy obtained a B.S. degree in biochemistry at Rutgers University, followed by a doctorate in molecular biology at the University of Pennsylvania School of Medicine. In 1994, she began postdoctoral research at Princeton University in the laboratory of Arnold J. Levine, Ph.D., the co-discoverer of p53. In 1998, Murphy became an Assistant Professor at Fox Chase Cancer Center, where she was promoted to Associate Professor in 2003, and Full Professor in 2011. She joined The Wistar Institute in 2011 and became Program Leader of the Molecular and Cellular Oncogenesis Program in 2012. Murphy is an adjunct professor at Drexel University College of Medicine and The Perelman School of Medicine at the University of Pennsylvania.

Michael Leapman, MD was drawn to the field of urology for the opportunity to care for patients with urologic cancers. He aims, above all, to deliver the highest level of care possible with the utmost consideration and compassion for the impact that cancer places on patients, as well as their families, friends and communities. Dr. Leapman graduated from Cornell University where he majored in Neurobiology and Behavior, and received his medical school degree from the University of Maryland in Baltimore. He completed his General Surgery and Urology training at the Mount Sinai Hospital in New York, NY. Subsequently, he completed a urologic oncology fellowship at the University of California San Francisco (UCSF) accredited by the Society of Urologic Oncology. He joined the faculty at the Yale University School of Medicine and Yale Cancer Center in 2016, specializing in urologic oncology with a joint appointment at the West Haven Veterans Affairs Medical Center.

Dr. Cecchini focuses on developing new treatments for patients living with advanced gastrointestinal cancers. His specific research includes leveraging innovating DNA damaging therapies as a strategy to enhance the immune response. He has participated as both a principal investigator or sub-investigator on more than 100 clinical trials. This includes cooperative group studies, industry studies, as well as investigator initiated clinical trials. He is also the national principal investigator for multiple studies. In addition to his clinical research, Dr. Cecchini collaborates with multiple laboratories to perform bench to bedside research to enhance treatment options for patients living with gastrointestinal cancers. He currently receives research funding through his NIH K08 Career Development Award which is evaluating the relationship between DNA damage and the immune response for gastrointestinal cancers. He was also awarded a Young Investigator Award from the Conquer Cancer Foundation, during his fellowship.

am board certified in both medical oncology and hospice and palliative medicine, which I feel helps me treat the "whole person" and not just a disease. As the Chief Patient Experience Officer at Smilow Cancer Hospital, I enjoy thinking about improving care, especially where the provider and patient experience overlaps. As a breast oncologist, I have a busy practice and enjoy taking care of women with newly diagnosed breast cancer. As the director of the Yale Survivorship Clinic, one of the nation’s only multi-disciplinary clinics specializing in cancer survivorship, I learn from patients about key issues after treatment and this informs my role as Chair of the NCCN Survivorship Guidelines. My research focuses on healthy lifestyles and quality of life after cancer. I am a facilitator for Relationship-Centered Communication Workshop that address how we develop therapeutic relationships with our patients and each other. Learn more about Dr. Tara Sanft>> Education & Training Fellowship Northwestern University, Chicago, Illinois (2010) Fellowship Northwestern University, Chicago, Illinois (2010) Resident Northwestern University Feinberg School of Medicine (2007) MD Medical College Wisconsin (2004)

Dr. Raj’s research focuses on using patient and clinician perspectives to improve healthcare quality. She uses mixed methods approaches to study ways of integrating caregivers into health care teams for older adults and patients with cancer with the goal of improving the quality of care for patients and supporting well-being among caregivers. For example, she examines the potential for health information technologies to support caregiver inclusion in health care visits. Her research also explores the ethical and social implications of these different health information technologies, including privacy and trust implications of health information sharing.

LJI Associate Professor Sonia Sharma, Ph.D., is an expert in using unbiased, genome-scale approaches to unravel innate immunity, the body’s early immune response to microbial pathogens and neoplastic cells. Innate immunity has also been implicated as a common causal factor in many inflammatory, allergic and autoimmune diseases. Dr. Sharma integrates cutting-edge genetics, biochemistry, cell biology, computational and translational approaches to define the key genetic mechanisms regulating cellular innate immunity and determine how they impact human health and disease.
Dr. Sharma has an outstanding record of research accomplishments, including high impact discoveries published in top scientific journals. Her work has made her an internationally recognized expert in the use of high throughput, genome scale approaches, in particular RNA interference and CRISPR/Cas9, to dissect complex cellular signaling pathways and questions of immunological relevance. Her use of these technologies is a powerful tool that can be applied to any cellular pathway or disease process.
Dr. Sharma also directs the La Jolla Institute for Immunology's Sex-Based Differences in the Immune System Initiative, which aims to shed light on why many diseases affect men and women differently.

 works to increase reproductive efficiency in humans and animals by increasing our understanding of the ovary, oviduct, and uterus. Projects in his lab include understanding how the uterus stores nutrients to support early pregnancy, how endocrine disruption chemicals (EDCs) affect the function of the oviduct, and the early events in the development of ovarian cancer.
More information:
Approximately 50% of pregnancies are lost in both humans and livestock, with most losses occurring before or during embryo implantation. During this time embryos are dependent on secretions to support and regulate embryonic growth, while the uterine endometrium must prepare for implantation. Dean's lab is working to understand how nutrients, such as glucose, are taken up, stored by the uterus, and used by the embryo and endometrium during early pregnancy. Their goal is to undercover ways to increase fertility in humans and livestock.
Ovarian cancer is the 5th leading cause of cancer death in women. Part of the reason for this is a poor understanding of the early events in disease development. It is now clear that high-grade serous ovarian cancer (the most lethal subtype) originates in the fallopian tube epithelium and spreads to the ovary very early in disease development. The Dean lab is working to understand how these tumor cells recruit cancer associated fibroblasts and remodel the extracellular matrix in the ovary during colonization.
Affiliations:
Dean is an assistant professor in the  and the  in the  (ACES) at the .

Miriam Merad, MD, PhD, is the Chair of the Department of Immunology and Immunotherapy, the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC).
Dr. Merad is an internationally acclaimed physician-scientist and a leader in the fields of dendritic cell and macrophage biology with a focus on their contribution to human diseases. Dr. Merad identified the tissue resident  macrophage lineage and revealed its distinct role in organ physiology and pathophysiology. She established the contribution of this macrophage lineage to cancer progression and inflammatory diseases and is now working on the development of novel macrophage-targeted therapies for these conditions. In addition to her work on macrophages, Dr. Merad is known for her work on dendritic cells, a group of cells that control adaptive immunity. She identified a new subset of dendritic cells, which is now considered a key target of antiviral and antitumor immunity.
Dr. Merad leads the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) to bring immunology discoveries to the clinic. PrIISM integrates immunological research programs with synergistic expertise in biology, medicine, technology, physics, mathematics and computational biology to enhance our understanding of human immunology. She also founded the Human Immune Monitoring Center at Mount Sinai, one of the world’s most sophisticated research centers, which uses cutting-edge single-cell technology to understand the contribution of immune cells to major human diseases or treatment responses.
Dr. Merad has authored more than 200 primary papers and reviews in high profile journals. Her work has been cited several thousand times. She receives generous funding from the National Institutes of Health (NIH) for her research on innate immunity and their contribution to human disease, and belongs to several NIH consortia. She is an elected member of the American Society of Clinical Investigation and the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. She is the President-elect of the International Union of Immunological Societies (IUIS). In 2020, she was elected to the National Academy of Sciences in recognition of her contributions to the field of immunology.
Please visit Dr. Merad's Lab website: 

Sajid Khan, MD is an Associate Professor of Surgery (Oncology), Section Chief of Hepato-Pancreato-Biliary & Mixed Tumors at Yale School of Medicine, and Co-Director of Team Science at Yale Center for Clinical Investigation. Dr. Khan is nationally recognized for superb clinical care and excellence in cancer research. He earned his medical degree from SUNY Upstate Medical University in Syracuse, NY and is Board Certified in both Complex General Surgical Oncology and General Surgery. He completed general surgery training at Oregon Health & Science University in Portland, OR and Albert Einstein College of Medicine/Montefiore in Bronx, NY. He also completed a research fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center in New York, NY and a clinical and research fellowship in surgical oncology at University of Chicago Medical Center in Chicago, IL. . Dr. Khan is dedicated to improving the lives of cancer patients by his busy surgical practice, federally funded research, leadership by example, and kindness.
Dr. Khan's surgical oncology practice specializes in patients with tumors of the liver, pancreas, bile ducts, gallbladder, stomach, and colon. Additionally he treats individuals diagnosed with melanoma, sarcoma, neuroendocrine tumors, and pancreatic cysts. His commitment to his patients and their families incorporates a multidisciplinary team approach, excellent communication, and state of the art minimally invasive surgery to provide an exceptional patient experience. Nationally, he has been named Top Doctors in American by Castle Connolly and consistently ranks in the top 1 percentile rank for patient satisfaction.
Dr. Khan is a federally funded, well published, surgeon-scientist who uses modern molecular biology (focused on metabolomics and transcriptomics) to improve our understanding and treatment of patients with gastrointestinal cancers. His gastrointestinal surgical oncology focused research has been consistently funded by the National Institutes of Health/National Cancer Institute and incorporates principles of team science. The Khan Lab performs translational scientific research studying cancer metastasis and differences in tumor biology based on race/ethnicity and sex. Using molecular and clinical markers, the Khan Lab studies the scientific underpinnings of liver metastasis and identifies cancer patients who may benefit from liver surgery. In addition, his lab studies the relationship of tumor metabolites and RNA expression with race/ethnicity and sex. He also performs clinical outcomes research for all types of gastrointestinal cancers. His lab's research is regularly presented at national and international scientific meetings, published in prestigious scientific journals, and featured in national media outlets.
Dr. Khan is Chair of the Society of Surgery of the Alimentary Tract (SSAT) Research Committee, on the Editorial Board for the Annals of Surgical Oncology, and Institutional Representative for the Society of University Surgeons (SUS). He is an active member of the Society of Surgery of the Alimentary Tract (SSAT), Society of Surgical Oncology (SSO), Society of University Surgeons (SUS), National Comprehensive Cancer Center (NCCN), American College of Surgeons (ACS), Association for Academic Surgery (AAS), Southwest Oncology Group (SWOG), American Society of Clinical Oncology (ASCO), Yale Center for Clinical Investigation (YCCI), Yale Cancer Center, and Yale School of Medicine Admissions Committee.

 investigates bioactive peptides and proteins in foods that promote health benefits for reducing inflammation, markers of type 2 diabetes, cancer, and cardiovascular disease risk. She identifies and characterizes the functional properties of food components, notably flavonoids in ethnic teas, herbs, and berries.
More information: Molecular mechanisms of chemoprevention of bioactive food components, mainly proteins and flavonoids, and their safety. The de Mejia lab studies food components with health benefits; analysis, characterization and mechanism of action of antimutagenic and anticarcinogenic compounds in foods (legumes, oilseeds and vegetables). They currently are working with bioactive proteins in different legumes. The research group investigates the role of processing on the presence, concentration and physicochemical characteristics of proteins with biological potential against transformed human cells as well as their safety, such as allergenic potential. They also are studying the health benefits of tea, in particular the molecular mechanisms underlying the biological effects of ethnic teas used in folk medicine to combat several disorders, including cancer. This scientific study will introduce new materials to improve human health.
Affiliations: Dr. de Mejia is a professor in the  and the , both part of the  (ACES) at the . 

Oncologist Patricia LoRusso, DO, associate director of innovative medicine at Yale Medicine, has expertise in testing new treatments on patient volunteers who have advanced stages of cancer. Her passion is bringing research breakthroughs into the clinic to help patients with different types and stages of cancer.
The clinical trials at Yale Cancer Center offer access to experimental drugs that are sometimes a patient’s last and best hope, says Dr. LoRusso. Therapies that prove successful can advance through the U.S. Food and Drug Administration approval process. “Many of the drugs tested here will help generations of cancer patients,” says Dr. LoRusso. In her career, 14 cancer drugs she has performed clinical trials on, which she refers to as her “children,” have gone on to gain FDA approval.
Dr. LoRusso leads the Phase I clinical trials infusion center at Smilow Cancer Hospital at Yale New Haven. She infuses the center with a warm, team-focused approach that puts patients at the center of care. “We’re improving patients’ lives in Connecticut and beyond,” says Dr. LoRusso.

Dr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at the Keck School of Medicine of the University of Southern California. He is currently associate professor of clinical medicine in the Division of Medical Oncology, a member of the Gastrointestinal Cancers Program and director of the phase I drug development clinical program. He has been the medical director of the Clinical Investigations Support Office at the USC Norris Comprehensive Cancer Center since 2007.
His primary research interests include the development of novel drugs for the treatment of solid tumors, especially gastrointestinal malignancies, the design and conduct of phase I and II clinical trials to test these drugs, and translational research focused on developing prognostic and predictive markers in patients with GI malignancies. Dr. El-Khoueiry has established a national reputation in the area of hepatobiliary cancers clinical research; he is the co-chair of the hepatobiliary cancers committee of the Southwest Oncology Group (SWOG) and a member of the National Cancer Institute (NCI) hepatobiliary cancers task force. He is the principal investigator on several clinical trials that are evaluating the role of novel drugs for the treatment of biliary and hepatocellular cancers.
As the phase I program director, Dr. El-Khoueiry has formed an experienced and highly skilled phase I clinical research team and established an efficient infrastructure for the conduct of high quality and innovative phase I studies. He has also worked with basic scientists at the USC Norris Comprehensive Cancer Center to design phase I studies to test novel compounds or novel combinations that had undergone pre-clinical testing at USC.
Dr. El-Khoueiry is frequently invited to give lectures nationally about gastrointestinal malignancies, particularly hepatobiliary cancers, and has a large number of peer-reviewed publications in his areas of research.

I am a breast medical oncologist and serve as the Medical Co-Director for Cancer Survivorship and Translational Behavioral Science Program at the Sylvester Comprehensive Cancer Center. I am also the Associate Director of Community Outreach of the Breast Cancer Program at Sylvester-Plantation. Since graduating from a Hematology Oncology Fellowship in 2008, I dedicated my career exclusively to building expertise in breast cancer prevention, treatment, and survivorship. Immediately after my fellowship, I joined Memorial Cancer Institute in Broward County, where I had the privilege to participate in several committees focused on patient satisfaction and quality improvement.

My goal was always to provide outstanding care that not only offers standard treatments but participation in vital clinical trials that offer patients innovative treatments before their approval. I served as a member of the local IRB for 8 years prior to 2015, when I joined University of Miami. Since joining our institution, I was invited to become a PRMC member and a member of Social Behavior committee. I value this committee and their role of making sure best research is available to our patients, not only scientifically but also ethically. I am committed to bringing new trials to our Breast Cancer Program and I am serving as a Principal Investigator on more than 10 clinical trials at the present time. I am the chair-elect for the ASCO lead TAPUR clinical trial and the local PI for TAPUR.

I have worked closely with Dr. Crane and her team on this application entitled, Comparative Effectiveness of Lifestyle Interventions for Older Cancer Survivors and Their Caregivers: the VITALITY Trial and will serve as Co-Investigator for this study. I will serve as a champion for this study for recruitment and provide my clinical oncology expertise in breast cancer to address participant related issues that may arise during this study including determining patient eligibility on a case by case basis, participate in regular research meeting, data interpretation and dissemination of findings.